Physician profile
Krishan Kataria
NPI 1194158188
$1,161.16
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2021: $454 · 2022: $208.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $240.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.06 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $171.88 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $131.20 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $121.87 | 2021 | |
| Janssen Pharmaceuticals, INC | $121.72 | 2019 | |
| Genzyme Corporation | $110.47 | 2022 | |
| Amgen INC. | $62.58 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishan Kataria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.